MENLO PARK, Calif., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the Canaccord Genuity Medical Technology and Diagnostics Forum and at the 26th Annual Piper Jaffray Healthcare Conference.
The presentation at the Canaccord forum is scheduled for 2:30 p.m. ET on Thursday, November 20, 2014 at the Westin Grand Central in New York, and the presentation at the Piper Jaffray conference is scheduled for 3:00 p.m. ET on Wednesday, December 3, 2014 at The New York Palace in New York.
A replay of the presentations will be available via the investors section of the company's website at www.intersectENT.com prior to the start of the live presentations. The replay of each webcast will be available approximately 24 hours after the live presentation and will be archived for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets the first and only drug-eluting sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers. To learn more about Intersect ENT, please visit www.intersectENT.com.